Recent Updates
Recently added Catalysts
Trending News :
The freshest biotech headlines moving stocks right now, newest first.
Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
BBNX ▼ 7.57%
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
XENE ▼ 24.24%
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
RARE ▲ 15.71%
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
LSTA ▲ 16.33%
Lexaria Updates Financial Position
LEXX ▲ 18.26%
Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction
SGRY ▼ 4.16%Upcoming Catalysts That Could Move the Market
DT120 (lysergide) is the lead candidate from Defin (Read More)
FT839 is a next-generation, off-the-shelf dual-CAR (Read More)
No description available yet.
Zilganersen (ION373), developed by Ionis Pharmaceu (Read More)
Tegoprubart is an investigational anti-CD40L monoc (Read More)
IMNN-001 is IMUNON’s lead DNA-mediated immunothera (Read More)
OCU410 is currently undergoing an active Phase 1/2 (Read More)
AXPAXLI, also referred to as OTX-TKI, is Ocular Th (Read More)
EYP-1901 (vorolanib intravitreal insert) represent (Read More)
Etentamig (ABBV-383) is an investigational BCMA x (Read More)
Cemsidomide (CFT7455) is an orally bioavailable IK (Read More)
DYNE-253 is a preclinical candidate developed by D (Read More)
Latest Stocks News :
AYTUAytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
Aytu BioPharma will announce its fiscal 2026 full year and fourth quarter results on September 22, 2026. The company will hold a conference call and webcast at 4:30 p.m. Eastern time to discuss these results. Interested parties can join the call using provided dial-in information, and a replay will be available until October 6, 2026.
Read more →
ICUIOtsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection
Otsuka ICU Medical LLC has issued a voluntary recall for a lot of 0.9% Sodium Chloride Injection due to a labeling mix-up that may result in the product containing Potassium Chloride instead. This poses significant health risks, particularly for vulnerable populations. The recall affects products distributed in the U.S. between December 2025 and June 2026, and customers are advised to quarantine the affected products and return them.
Read more →NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGER
NOMAD Power Solutions has filed an expanded financial disclosure following its merger with NOMAD Transportable Power Systems. The report highlights the company's growing revenue, strategic growth initiatives, and the increasing demand for rapidly deployable power infrastructure. NOMAD's Voyager platform aims to address critical power needs across various sectors, including utilities and data centers.
Read more →
TVTXTravere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Travere Therapeutics, Inc. announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The presentation is scheduled for 10:30 a.m. ET and will be available via a live webcast on the company's investor page. A replay of the event will be accessible for 30 days post-presentation.
Read more →InfuSystem to Host Investor Webcast on September 24, 2026
InfuSystem has announced that it will host an investor webcast on September 24, 2026. This event aims to improve communication with investors and provide updates on the company's progress. The webcast reflects the company's commitment to transparency and investor engagement.
Read more →
BIIBPhase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
Biogen announced the publication of Phase 3 VALIANT study results for EMPAVELI, showing significant benefits in adolescents with C3G and primary IC-MPGN. The study revealed a 75% reduction in proteinuria and stabilization of kidney function. This treatment is now the only approved option for this age group, following a recent FDA label update. The findings underscore the potential of EMPAVELI to improve kidney health in young patients.
Read more →
PBYIPuma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Puma Biotechnology has launched the ALISCA®-Lung2 trial, a Phase II study evaluating the efficacy of alisertib combined with paclitaxel for patients suffering from advanced small cell lung cancer. This initiative represents a significant step forward in addressing treatment options for this challenging cancer type.
Read more →BBNXBeta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock
Beta Bionics, Inc. has successfully closed a public offering of 7,652,175 shares at $17.25 each, raising $172.5 million. The offering included pre-funded warrants and was fully subscribed by underwriters. The proceeds will be utilized for general corporate purposes, including the commercialization of their iLet Bionic Pancreas and expansion of manufacturing facilities.
Read more →
ARGXargenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
argenx SE announced the results of its Extraordinary General Meeting, appointing Thomas M. Brakel and Khurem Farooq as non-executive directors. The company emphasizes its commitment to scientific innovation and enhancing shareholder value. The appointments are seen as a strategic move to strengthen the Board as argenx aims for long-term growth and impact in immunology.
Read more →XENEXenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
Xenon Pharmaceuticals has submitted a New Drug Application for azetukalner to the FDA for the treatment of focal seizures. This submission is based on positive results from two clinical trials. The company has also paused enrollment in its psychiatry studies due to neuropsychiatric adverse events, although current participants remain active. Topline data for the major depressive disorder study is expected in Q1 2027.
Read more →